Revvity raised full-year organic growth guidance to 4%-5%, supported by diagnostics and improving life sciences demand.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-08-04 |
| Length | 58 minutes |
| EPS | $1.41 |
| EPS consensus | $1.23 |
| Revenue | $729.7M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY26 · Q4 FY25 · Q2 FY25 · Q1 FY25 · Q4 FY24
Read the full Q2 FY26 earnings call transcript
All RVTY earnings · Back to RVTY overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.